Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

According to Benzinga Pro, Pfizer's peer group average for short interest as a percentage of float is 3.60%, which means the ...

PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3... By Nate Raymond (NSE:RYMD) (Reuters) - Pfizer (NYSE:PFE) has resolved a lawsuit by ...

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

The stock's fall snapped a four-day winning streak.

We recently published a list of Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a look at ...

While Pfizer Ltd had reported Rs179 crore In the corresponding quarter of the previous fiscal, or March quarter of FY24, the net profit in the March 2025 quarter saw a sharp jump to ₹331 crore.

Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug candidate, SSGJ-707. SSGJ-707, a bispecific antibody targeting PD-1 and ...